atopic eczema: A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
387 |
4. Check minimum number of eventsNone |
387 |
5. Include endpointsNone |
387 |
6. Filter based on genotype QC (FinnGen only) |
387 |
Control definitions (FinnGen only)
- Control exclude
- L12_DERMATITISECZEMA
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- L20-L30
- Name in latin
- Erythrodermia universalis NAS
Similar endpoints
↥List of similar endpoints to
Exfoliative dermatitis
based on the number of shared cases.
Similar with more cases:
- Dermatitis and eczema
- Diseases of the skin and subcutaneous tissue
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 3058 | 1077 | 1960 |
| Only index persons | 2575 | 944 | 1631 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.05 | 0.03 | 0.05 |
| Only index persons | 0.05 | 0.03 | 0.06 |
| Median age at first event (years) | |||
| Whole population | 61.96 | 61.58 | 62.08 |
| Only index persons | 60.41 | 60.15 | 60.56 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 387 | 114 | 273 |
| Unadjusted period prevalence (%) | 0.10 | 0.04 | 0.12 |
| Median age at first event (years) | 61.76 | 56.30 | 64.04 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 353
- Matched controls
- 3531
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L26
ICD-10 Finland
Exfoliative dermatitis
+∞
323.0
306
*
D07AB08
ATC
desonide; topical
40.6
162.4
215
130
E000001
ATC
NA
25.0
147.4
248
304
134
Kela drug reimbursment
General erythroderma
1968.8
140.5
127
*
L20.0
ICD-10 Finland
Besnier prurigo
+∞
139.0
124
*
D07AC01
ATC
betamethasone; topical
22.1
135.8
293
637
E0000UV
ATC
NA
20.6
128.5
296
710
D07AA02
ATC
hydrocortisone; topical
20.3
114.0
190
191
D07AB02
ATC
hydrocortisone butyrate; topical
13.4
103.7
240
483
E000003
ATC
NA
43.2
97.2
121
42
L30.9
ICD-10 Finland
Dermatitis, unspecified
17.8
96.6
166
167
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
20.2
95.6
154
130
D07AC13
ATC
mometasone; topical
10.3
85.7
229
536
E000002
ATC
NA
17.2
84.1
144
136
317
Kela drug reimbursment
Topical pimecrolimus and tacrolimus
+∞
82.6
76
*
D05BB02
ATC
acitretin; oral
56.1
75.9
89
21
D02AE01
ATC
carbamide; topical
24.1
74.5
109
64
TQW80
NOMESCO Finland
Local dermatologic skincare
68.4
74.1
84
16
H02AB06
ATC
prednisolone; systemic
9.0
72.6
282
1081
D07XC01
ATC
betamethasone, combinations; topical
11.3
69.0
147
210
E000006
ATC
NA
23.1
68.3
101
60
D07BB04
ATC
hydrocortisone butyrate and antiseptics; topical
11.7
63.7
130
167
D11AH01
ATC
tacrolimus; topical
+∞
60.1
56
*
D02AX
ATC
Other emollients and protectives
49.0
59.0
71
18
D07BA04
ATC
hydrocortisone and antiseptics; topical
12.1
55.1
108
124
L30.3
ICD-10 Finland
Infective dermatitis
66.6
53.6
61
11
L04AX03
ATC
methotrexate; systemic (immunosuppressants)
11.1
51.4
105
129
WXQ27
NOMESCO Finland
UVB narrow spectrum light therapy
105.9
50.4
54
6
L40.0
ICD-10 Finland
Psoriasis vulgaris
18.2
49.0
78
54
D07AD01
ATC
clobetasol; topical
8.1
48.4
123
218
L04AD01
ATC
ciclosporin; systemic
31.2
45.1
60
23
L20.9
ICD-10 Finland
Atopic dermatitis, unspecified
+∞
43.6
41
*
XQ802
NOMESCO Finland
Epicutan test
70.7
43.5
49
8
N05BB01
ATC
hydroxyzine; systemic
14.3
42.2
74
64
R06AE07
ATC
cetirizine; oral
4.7
40.3
212
861
D11AX14
ATC
[U] tacrolimus; topical
+∞
37.1
35
*
D09AB01
ATC
zinc bandage without supplements; topical
50.0
36.9
44
10
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
10.2
34.3
71
85
E000007
ATC
NA
12.5
32.5
60
57
C84.0
ICD-10 Finland
Mycosis fungoides
+∞
30.7
29
*
D11AH02
ATC
pimecrolimus; topical
+∞
28.5
27
*
L04AA01
ATC
[U] ciclosporin; systemic
28.2
28.1
38
15
R06AE09
ATC
levocetirizine; oral
5.3
24.7
83
194
L20
ICD-10 Finland
Atopic dermatitis
+∞
24.2
23
*
D07BC01
ATC
betamethasone and antiseptics; topical
5.3
23.2
76
172
R06AX27
ATC
desloratadine; oral
3.7
22.6
121
437
D05AX52
ATC
calcipotriol, combinations; topical
7.2
22.6
57
92
D07CC01
ATC
betamethasone and antibiotics; topical
5.0
22.4
78
188
D05AX02
ATC
calcipotriol; topical
9.6
21.6
45
53
L40.8
ICD-10 Finland
Other psoriasis
36.4
21.4
27
8
69100
ICD-8 Finland
Infantile eczema and related conditions, Eczema atopicum. Prurigo Besnier. Eczema pruriginosum allergicum
+∞
21.0
20
*
319
Kela drug reimbursment
Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis)
77.7
19.9
22
*
L30.8
ICD-10 Finland
Other specified dermatitis
27.9
19.4
26
10
L30.0
ICD-10 Finland
Nummular dermatitis
12.4
17.9
32
28
395
Kela drug reimbursment
Dupilumab
+∞
17.9
17
*
L27.0
ICD-10 Finland
Generalized skin eruption due to drugs and medicaments
52.8
17.2
20
*
J01DB01
ATC
cefalexin; oral
3.2
17.0
296
2191
XQ800
NOMESCO Finland
Prick test
6.8
16.9
43
70
A46
ICD-10 Finland
Erysipelas
3.6
16.5
84
284
PJ2AE
NOMESCO Finland
Lymphnode ultrasound examination
31.7
16.3
21
7
D01AC20
ATC
imidazoles/triazoles in combination with corticosteroids; topical
3.1
16.2
106
430
D07AC14
ATC
methylprednisolone aceponate; topical
8.2
16.1
36
48
D11AH05
ATC
dupilumab; topical
+∞
15.7
15
*
L40.9
ICD-10 Finland
Psoriasis, unspecified
21.2
15.3
22
11
E000004
ATC
NA
12.1
15.0
27
24
H02AB07
ATC
prednisone; oral
3.5
15.0
76
254
D05AX03
ATC
calcitriol; topical
19.4
14.9
22
12
RS340
NOMESCO Finland
NA
83.6
14.7
16
*
D11AX15
ATC
[U] pimecrolimus; topical
+∞
14.7
14
*
L44.0
ICD-10 Finland
Pityriasis rubra pilaris
+∞
14.7
14
*
6918B
ICD-9 Finland
Atopic dermatitis and related conditions, Other atopic dermatitis and related conditions[ECZEMA ATOPICUM]
+∞
14.7
14
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.4
14.2
178
1039
L23.0
ICD-10 Finland
Allergic contact dermatitis due to metals
145.3
13.5
14
*
S87
ICPC
Dermatitis/atopic eczema
17.6
13.1
20
12
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.3
12.6
69
242
L29.9
ICD-10 Finland
Pruritus, unspecified
21.0
12.6
18
9
L01BA01
ATC
methotrexate; systemic (folic acid analog.)
7.6
12.6
29
41
WXQ10
NOMESCO Finland
Psoralen - Ultraviolet A therapy with systemic sensitivisation
+∞
12.6
12
*
L23.3
ICD-10 Finland
Allergic contact dermatitis due to drugs in contact with skin
+∞
12.6
12
*
L28.1
ICD-10 Finland
Prurigo nodularis
134.5
12.5
13
*
R06AX22
ATC
ebastine; oral
3.0
11.5
72
277
C84.1
ICD-10 Finland
Sézary disease
+∞
11.5
11
*
9700/3-C44.9
ICD-O-3
Mycosis fungoides of skin, NOS
+∞
11.5
11
*
J30.10
ICD-10 Finland
Allergic rhinitis due to pollen
7.0
11.5
28
43
WXQ12
NOMESCO Finland
Psoralen - Ultraviolet A therapy with local sensitivisation
123.8
11.5
12
*
H02AB04
ATC
methylprednisolone; systemic
3.1
11.4
68
254
L53.9
ICD-10 Finland
Erythematous condition, unspecified
26.0
11.2
15
6
H02AB09
ATC
hydrocortisone; systemic
9.7
11.2
22
24
L04AX01
ATC
azathioprine; systemic
6.2
11.0
29
50
RS221
NOMESCO Finland
NA
11.7
10.7
19
17
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
3.8
10.7
46
134
L23.9
ICD-10 Finland
Allergic contact dermatitis, unspecified cause
113.2
10.5
11
*
L27.2
ICD-10 Finland
Dermatitis due to ingested food
+∞
10.5
10
*
L23.2
ICD-10 Finland
Allergic contact dermatitis due to cosmetics
+∞
10.5
10
*
L20.8
ICD-10 Finland
Other atopic dermatitis
+∞
10.5
10
*
A41.0
ICD-10 Finland
Sepsis due to Staphylococcus aureus
10.0
10.4
20
21
J01FF01
ATC
clindamycin; systemic
2.4
10.4
109
562
RS121
NOMESCO Finland
NA
24.2
10.3
14
6
L50.0
ICD-10 Finland
Allergic urticaria
10.0
9.9
19
20
RJ411
NOMESCO Finland
NA
26.9
9.9
13
5
J45.0
ICD-10 Finland
Predominantly allergic asthma
3.8
9.6
41
119
C03CA01
ATC
furosemide; systemic
2.2
9.5
124
701
D06AX01
ATC
fusidic acid; topical (antibiotics for topical use)
3.3
9.2
46
151
L28.0
ICD-10 Finland
Lichen simplex chronicus
37.7
9.1
11
*
RJ420
NOMESCO Finland
NA
24.7
9.0
12
5
L40.5
ICD-10 Finland
Arthropathic psoriasis
8.6
8.7
18
22
C10AB05
ATC
fenofibrate; oral
9.3
8.6
17
19
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
5.0
8.6
27
58
6961A
ICD-9 Finland
Psoriasis and similar disorders, Other psoriasis[PSORIASIS VULGARIS]
20.6
8.5
12
6
J01DA01
ATC
[U] cefalexin; systemic
2.0
8.5
218
1598
L23.8
ICD-10 Finland
Allergic contact dermatitis due to other agents
+∞
8.4
8
*
RS311
NOMESCO Finland
NA
+∞
8.4
8
*
D11AH04
ATC
alitretinoin; oral
+∞
8.4
8
*
C01CA24
ATC
epinephrine; parenteral
4.4
8.3
29
70
L50.9
ICD-10 Finland
Urticaria, unspecified
8.4
8.2
17
21
EBA15
NOMESCO Finland
Extraction of large number of teeth
4.5
7.9
27
64
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.1
7.9
107
609
J01DA09
ATC
[U] cefadroxil; inhalant, oral
2.1
7.8
102
572
XW000
NOMESCO Finland
Bone marrow biopsy
5.0
7.8
24
51
JN4BD
NOMESCO Finland
Extensive body CT
2.7
7.8
53
215
J45.9
ICD-10 Finland
Asthma, unspecified
2.4
7.8
68
315
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
2.3
7.7
81
410
S01GX01
ATC
cromoglicic acid; ophthalmic
2.4
7.6
67
309
D07AC03
ATC
desoximetasone; topical
9.2
7.6
15
17
XQ848
NOMESCO Finland
Dermatological photography
7.1
7.4
17
25
6929X
ICD-9 Finland
Contact dermatitis and other eczema, Unspecified cause[DERMATITITIS ARTEFACTA NUD]
+∞
7.3
7
*
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.0
7.3
103
592
E27.3
ICD-10 Finland
Drug-induced adrenocortical insufficiency
30.7
7.2
9
*
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
2.7
7.1
48
192
SPAT1148
SPAT
Treatment of chronic ulcer or burn
2.5
7.1
57
253
R06AX13
ATC
loratadine; oral
2.5
7.0
57
255
RS224
NOMESCO Finland
NA
40.8
6.8
8
*
J44.8
ICD-10 Finland
Other specified chronic obstructive pulmonary disease
2.4
6.5
56
259
L04AC05
ATC
ustekinumab; parenteral
71.0
6.4
7
*
L21.0
ICD-10 Finland
Seborrhoea capitis
71.0
6.4
7
*
L08.0
ICD-10 Finland
Pyoderma
14.6
6.4
10
7
L04AB04
ATC
adalimumab; parenteral
8.4
6.4
13
16
D64.9
ICD-10 Finland
Anaemia, unspecified
2.6
6.4
47
199
S91
ICPC
Psoriasis
11.3
6.3
11
10
S21
ICPC
Skin texture symptom/complaint
2.6
6.3
47
200
69619
ICD-8 Finland
Psoriasis and similar disorders, Psoriasis alia sive NUD (vulgaris)
18.4
6.3
9
5
1XX25
NOMESCO Finland
NA
+∞
6.3
6
*
WW409
NOMESCO Finland
Other aferesis
+∞
6.3
6
*
ZX196
NOMESCO Finland
NA
+∞
6.3
6
*
6929B
ICD-9 Finland
Contact dermatitis and other eczema, Unspecified cause[ECZEMA INFECTIOSUM]
+∞
6.3
6
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
3.2
6.2
30
98
N06AA12
ATC
doxepin; systemic
3.4
6.0
27
83
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
98
128
9.91
74.07
2.1
1.2
3490.9
187.4
u/ml
4.95
93
112
32
16
21.71
42.01
2.2
1.8
—
—
—
0
0
33
19
18.89
40.69
2.2
1.7
10.3
13.3
%
—
22
7
25
18
14.78
27.31
3.2
2.1
425.3
329.6
e6/l
0.44
16
12
270
1655
3.09
23.36
18.0
9.1
4.5
4.2
e9/l
1.41
252
1441
92
309
3.59
23.02
5.7
3.6
—
—
—
0
0
236
1375
2.84
21.90
14.4
6.1
24.0
26.5
%
3.00
230
1278
233
1351
2.82
21.78
13.7
5.9
58.9
58.2
%
0.36
228
1266
71
242
3.37
17.06
1.8
3.2
66.9
65.8
g/l
0.63
64
216
29
55
5.62
14.90
4.0
3.3
62.4
57.5
%
0.99
29
55
28
52
5.73
14.70
3.9
3.1
4.8
4.4
e9/l
0.43
28
52
23
36
6.73
14.26
1.1
1.1
9.2
1.4
u/ml
1.08
17
16
18
9
20.89
12.57
1.8
1.0
11.2
7.7
ug/l
—
18
9
100
494
2.38
11.59
4.5
3.9
0.8
0.8
mmol/l
2.82
91
464
86
401
2.47
11.30
9.0
6.3
1.1
1.0
mmol/l
0.65
80
368
127
736
2.08
9.73
2.6
2.0
2.9
3.2
mg/l
0.74
109
626
35
109
3.43
9.56
1.5
2.5
—
—
—
0
0
35
109
3.43
9.56
1.5
2.5
7.3
7.3
g/l
0.00
23
79
35
109
3.43
9.56
1.5
2.5
4.0
3.8
g/l
0.47
22
76
31
92
3.58
9.11
1.5
2.9
0.8
1.0
g/l
0.09
25
79
32
99
3.43
8.83
1.5
2.6
3.4
3.2
g/l
0.24
22
77
285
2243
2.03
8.53
11.8
8.0
84.8
79.0
u/l
1.05
275
2089
271
2105
1.96
8.31
5.7
3.9
15.4
12.5
mm/h
1.85
264
1915
31
99
3.32
8.15
1.5
2.6
10.1
10.6
g/l
0.38
25
85
181
1254
1.83
7.78
7.0
5.2
34.3
35.2
g/l
1.19
167
1170
12
8
15.42
7.76
2.3
1.5
—
—
—
0
0
79
418
2.12
7.50
3.1
2.7
25.5
23.0
%
0.63
74
368
168
1150
1.81
7.42
3.5
2.8
206.3
172.2
ug/l
0.57
155
1046
164
1129
1.79
7.00
4.1
3.4
—
—
—
0
0
27
89
3.19
6.76
1.6
2.7
37.3
37.4
g/l
0.04
22
73
94
557
1.91
6.43
1.4
1.2
4.9
1.3
u/ml
0.86
28
154
206
1543
1.72
6.33
8.6
6.9
10.4
12.1
umol/l
2.67
198
1463
167
1188
1.71
6.15
2.3
2.0
86.4
95.0
pmol/l
2.22
121
628
20
59
3.52
5.94
1.4
1.8
—
—
—
0
0
44
208
2.26
5.48
2.2
1.7
—
—
—
0
0
22
73
3.14
5.46
1.2
1.7
—
—
—
0
0
137
950
1.68
5.39
4.3
3.5
2.3
2.3
mmol/l
0.13
117
827
13
30
4.45
5.33
1.2
1.3
—
—
—
0
0
15
40
3.86
5.14
1.2
1.2
—
—
—
0
0
23
82
2.92
5.07
1.2
1.3
—
—
—
0
0
92
580
1.77
5.06
2.0
1.7
1196.5
1200.4
nmol/l
0.01
72
442
11
23
4.89
5.04
1.3
1.2
—
—
—
0
0
112
748
1.70
5.01
3.7
2.9
380.1
9270.9
umol/l
3.90
98
646
129
899
1.65
4.90
2.1
2.1
337.8
281.0
u/l
0.16
123
843
105
694
1.70
4.87
1.9
1.5
20.2
20.0
nmol/l
0.04
94
585
33
146
2.38
4.79
1.5
2.3
1.6
1.5
g/l
0.30
26
129
148
1078
1.60
4.66
2.7
2.3
71.8
77.0
nmol/l
1.59
139
946
22
81
2.82
4.59
2.2
1.5
—
—
—
0
0
18
59
3.15
4.57
2.3
2.9
16.2
16.0
%
—
9
35
187
1448
1.56
4.48
9.8
7.1
1.2
1.2
mmol/l
0.24
145
1208
7
6
11.85
4.29
1.0
1.0
—
—
—
0
0
220
1778
1.55
4.28
6.3
4.9
7.0
6.8
mmol/l
0.51
211
1669
13
36
3.70
4.24
3.8
2.6
—
—
—
0
0
122
865
1.60
4.22
3.7
3.3
0.4
0.6
e6/l
0.71
104
655
13
38
3.51
3.93
2.1
3.0
34.6
33.4
pg
0.63
13
38
24
101
2.47
3.90
2.9
4.5
30.7
34.7
mg/l
0.35
17
81
24
101
2.47
3.90
2.9
4.5
66.8
134.7
mg/l
0.48
17
80
20
77
2.68
3.87
3.1
2.4
—
—
—
0
0
15
51
3.02
3.61
1.9
1.7
—
—
—
0
0
10
26
3.92
3.54
1.2
1.2
—
—
—
0
0
10
26
3.92
3.54
1.6
3.5
—
—
—
0
0
168
1319
1.48
3.52
8.9
6.3
1.2
1.2
mmol/l
0.19
156
1174
56
343
1.74
3.36
2.2
1.8
2.1
1.6
%
2.79
51
298
236
1998
1.46
3.27
5.5
3.5
14.7
14.9
pmol/l
0.58
220
1762
62
394
1.68
3.26
1.4
1.5
—
—
—
0
0
124
932
1.49
3.16
3.9
4.1
6.9
10.0
mg/mmol
0.73
83
624
20
87
2.37
3.06
1.4
1.4
—
—
—
0
0
14
51
2.81
3.02
1.4
1.1
—
—
—
0
0
14
51
2.81
3.02
1.4
1.1
—
—
—
0
0
74
503
1.58
2.98
2.5
1.9
—
—
—
0
0
48
293
1.73
2.92
5.5
4.6
1.8
1.7
mmol/l
0.09
38
227
10
30
3.40
2.92
1.7
1.9
—
—
—
0
0
44
262
1.77
2.92
2.4
2.2
53.0
219.9
u/l
0.43
36
219
123
936
1.46
2.91
2.5
2.5
49.7
55.8
u/l
1.87
116
870
55
354
1.65
2.76
3.0
3.3
5.1
9.4
umol/l
3.71
50
320
15
60
2.56
2.73
3.3
2.0
—
—
—
0
0
36
206
1.82
2.73
5.0
4.0
1.2
1.8
mmol/l
0.31
30
152
18
82
2.25
2.51
3.3
1.9
—
—
—
0
0
18
82
2.25
2.51
3.6
1.9
—
—
—
0
0
11
39
2.87
2.49
1.7
1.9
—
—
—
0
0
7
16
4.43
2.48
9.9
13.0
765.7
915.9
nmol/l
—
7
16
7
16
4.43
2.48
13.0
15.2
1079.7
1553.6
nmol/l
—
7
16
6
12
5.06
2.41
6.0
2.9
101.2
95.1
%
—
6
12
75
536
1.50
2.40
4.6
3.2
2.4
2.4
mmol/l
0.18
62
468
14
59
2.42
2.32
1.2
1.3
—
—
—
0
0
7
18
3.94
2.26
1.7
2.1
—
—
—
0
0
84
622
1.45
2.25
1.9
1.8
380.3
431.6
pmol/l
0.81
72
519
84
625
1.44
2.19
2.2
1.7
1.9
1.5
mg/l
0.40
62
494
167
1396
1.35
2.16
6.1
5.0
0.0
0.0
estimate
0.00
51
275
9
30
3.05
2.16
1.2
1.2
—
68.0
—
0
5
7
19
3.73
2.16
1.7
2.1
—
—
—
0
0
6
14
4.34
2.16
1.0
1.3
—
—
—
0
0
169
1417
1.34
2.14
4.5
3.6
0.0
0.0
estimate
0.00
48
262
218
1898
1.34
2.13
4.4
3.2
74.8
53.0
u/l
1.27
210
1766
102
791
1.39
2.11
4.3
3.7
0.0
0.0
estimate
0.50
46
267
8
25
3.25
2.10
1.8
1.9
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
21
110
1.96
2.10
3.8
2.7
0.4
0.3
u/ml
0.31
13
65
9
31
2.95
2.08
1.1
1.1
—
—
—
0
0
167
1404
1.33
2.05
4.5
3.6
0.0
0.0
estimate
0.00
49
273
6
15
4.05
2.04
1.3
1.1
—
—
—
0
0
12
50
2.44
2.04
1.6
1.8
—
—
—
0
0
51
348
1.54
2.03
2.0
1.9
—
—
—
0
0
12
52
2.35
1.89
1.3
1.2
—
—
—
0
0
57
405
1.48
1.89
1.4
1.3
4.7
14.1
u/ml
1.48
22
161
7
22
3.22
1.89
1.0
1.2
—
—
—
0
0
16
79
2.07
1.88
1.1
1.3
—
—
—
0
0
16
79
2.07
1.88
1.1
1.3
—
—
—
0
0
15
74
2.07
1.77
2.4
2.3
135.4
131.2
g/l
—
10
52
5
13
3.88
1.72
2.4
1.0
—
—
—
0
0
12
55
2.22
1.69
1.9
1.8
—
—
—
0
0
16
83
1.97
1.67
1.2
1.3
—
—
—
0
0
23
135
1.75
1.66
6.7
4.5
24.9
24.9
mmol/l
0.01
23
125
5
14
3.60
1.62
1.0
1.4
—
—
—
0
0
5
14
3.60
1.62
1.0
1.4
—
—
—
0
0
13
63
2.10
1.61
1.3
1.5
—
—
—
0
0
74
569
1.37
1.60
3.4
3.9
902.5
423.4
ng/l
0.54
62
465
49
350
1.46
1.60
1.9
1.8
—
—
—
0
0
8
33
2.45
1.54
1.4
1.9
—
—
—
0
0
5
15
3.36
1.53
1.2
1.3
—
—
—
0
0
6
21
2.89
1.51
1.0
1.2
—
—
—
0
0
132
1114
1.28
1.49
4.6
3.7
—
—
—
0
0
12
59
2.07
1.45
1.9
1.8
—
—
—
0
0
5
16
3.15
1.44
1.0
1.4
—
—
—
0
0
5
16
3.15
1.44
1.0
1.4
—
—
—
0
0
68
525
1.36
1.44
3.1
3.0
0.9
1.0
e6/l
0.07
43
310
29
190
1.57
1.42
1.5
1.6
—
—
—
0
0
88
710
1.31
1.39
4.4
2.5
—
—
—
0
0
0
37
0.00
1.35
0.0
1.2
—
7.8
—
0
26
13
68
1.94
1.35
1.5
1.5
28254.7
12725.5
e6/l
—
6
51
308
2898
1.31
1.33
27.2
15.3
25.1
25.9
mg/l
0.18
280
2310
115
967
1.27
1.32
3.3
3.3
3143.2
1639.8
ng/l
0.58
108
836
9
44
2.07
1.27
1.6
1.2
—
56.5
—
0
5
6
25
2.42
1.25
1.2
1.0
—
—
—
0
0
10
49
2.07
1.23
2.1
1.8
—
—
—
0
0
5
19
2.65
1.22
2.4
3.9
—
—
—
0
0
13
224
0.57
1.21
1.8
1.7
—
—
—
0
0
19
117
1.66
1.20
2.0
1.7
—
—
—
0
0
20
125
1.63
1.20
3.5
1.9
—
—
—
0
0
12
64
1.90
1.19
1.8
1.5
230.8
242.6
miu/ml
—
5
32
8
38
2.13
1.19
1.6
1.6
—
—
—
0
0
29
200
1.49
1.16
1.9
1.5
—
—
—
0
0
8
39
2.07
1.16
1.6
1.5
—
—
—
0
0
8
39
2.07
1.16
1.6
1.5
—
—
—
0
0
8
39
2.07
1.16
1.6
1.5
—
—
—
0
0
8
40
2.02
1.12
1.6
1.5
—
—
—
0
0
8
40
2.02
1.12
1.6
1.5
—
—
—
0
0
72
877
0.78
1.11
2.9
3.1
0.5
0.8
ug/l
6.24
55
574
24
161
1.52
1.09
3.8
3.7
23.9
24.8
mmol/l
0.52
24
155
64
513
1.30
1.07
3.5
3.2
1.4
1.5
e6/l
0.14
38
301
54
423
1.32
1.06
1.4
1.2
25.4
39.8
iu/ml
0.64
22
133
13
75
1.76
1.04
1.5
1.3
—
—
—
0
0
20
131
1.56
1.02
1.1
1.4
—
—
—
0
0
17
108
1.60
0.98
2.8
3.2
—
—
—
0
0
10
54
1.87
0.97
1.3
1.2
—
—
—
0
0
139
1230
1.20
0.96
4.5
3.9
47.8
42.7
ng/l
0.11
103
911
269
2531
1.21
0.93
6.0
4.2
1.9
2.4
mu/l
0.60
253
2260
36
274
1.35
0.88
2.2
2.8
9.3
8.1
ug/l
0.15
31
251
12
73
1.66
0.82
1.5
1.5
—
—
—
0
0
6
33
1.83
0.79
2.3
4.1
—
—
—
0
0
6
33
1.83
0.79
1.0
1.1
—
—
—
0
0
150
1357
1.17
0.79
6.3
4.3
—
—
—
0
0
106
1194
0.85
0.75
3.6
4.3
16.7
21.6
%
2.51
48
583
7
38
1.86
0.74
4.7
3.9
363.7
316.4
umol/l
—
7
32
137
1508
0.86
0.73
4.5
5.0
3.9
2.9
ug/l
0.25
119
1329
27
204
1.35
0.71
3.5
3.5
128.9
128.8
g/l
0.00
27
199
7
41
1.72
0.70
5.1
2.0
—
—
—
0
0
7
42
1.68
0.68
1.7
1.5
—
—
—
0
0
20
267
0.74
0.63
2.7
1.9
—
—
—
0
0
277
2880
0.87
0.61
5.9
4.9
2.6
2.7
mmol/l
1.36
257
2633
7
113
0.61
0.59
3.0
1.6
—
—
—
0
0
0
23
0.00
0.58
0.0
1.3
—
—
—
0
0
38
311
1.25
0.58
2.1
2.0
13.8
13.5
nmol/l
0.07
38
274
284
2731
1.15
0.57
25.8
14.3
79.9
78.9
ml/min/173m2
0.30
257
2273
6
38
1.59
0.54
5.7
2.1
—
—
—
0
0
45
382
1.20
0.50
9.2
7.3
1.1
1.2
mmol/l
0.02
34
292
18
233
0.76
0.48
1.9
1.4
—
—
—
0
0
32
383
0.82
0.46
4.0
4.7
30.0
31.5
%
0.23
23
256
269
2595
1.12
0.45
27.3
16.2
39.1
40.0
%
0.73
179
1809
80
722
1.14
0.43
2.0
1.6
1.5
1.4
mmol/l
0.28
67
589
5
31
1.62
0.43
1.4
1.3
—
—
—
0
0
6
91
0.65
0.43
1.3
1.5
—
—
—
0
0
5
33
1.52
0.41
1.2
1.1
—
—
—
0
0
19
235
0.80
0.38
2.7
1.8
—
—
—
0
0
272
2796
0.91
0.35
5.5
4.5
1.3
1.4
mmol/l
1.15
252
2556
26
221
1.19
0.31
4.3
3.4
61.9
64.3
ml/min/173m2
—
10
92
37
325
1.15
0.31
2.5
4.9
4.9
52.5
ug/l
1.20
30
275
162
1685
0.93
0.25
3.0
2.9
—
—
—
0
0
47
430
1.11
0.22
24.2
26.7
1.3
1.2
inr
—
10
45
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
276
2810
0.94
0.20
6.6
4.5
4.4
4.5
mmol/l
0.96
258
2586
0
14
0.00
0.20
0.0
2.7
—
—
—
0
0
305
3006
1.07
0.18
28.7
17.9
4.0
4.0
mmol/l
0.85
299
2926
7
60
1.17
0.18
2.1
1.1
36.7
53.9
u/l
—
7
50
261
2649
0.95
0.14
6.5
6.1
40.1
40.7
mmol/mol
0.42
242
2443
33
356
0.92
0.14
13.5
7.1
—
—
—
0
0
303
2998
1.05
0.12
28.7
17.8
139.0
139.7
mmol/l
4.69
298
2921
5
45
1.11
0.10
1.2
1.1
—
—
—
0
0
5
46
1.09
0.09
1.0
1.3
109.0
15.1
e6/l
—
5
41
5
46
1.09
0.09
1.0
1.3
8.6
176.9
e6/l
—
5
41
5
61
0.82
0.08
1.2
1.1
—
—
—
0
0
5
60
0.83
0.08
1.0
1.1
—
—
—
0
0
7
85
0.82
0.07
2.7
1.5
—
—
—
0
0
14
133
1.05
0.01
1.0
1.0
—
—
—
0
0
273
2722
1.01
0.01
6.3
4.0
1.4
1.3
mmol/l
2.38
254
2475
15
144
1.04
0.00
1.5
1.3
—
28.8
—
0
11
279
2786
1.01
0.00
5.2
4.6
6.1
6.0
mmol/l
0.16
262
2522
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
4.4
—
0
5
5
57
0.88
0.00
1.2
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
69.4
—
0
5
0
7
0.00
0.00
0.0
3.0
—
12.6
—
0
7
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
3.4
—
—
—
0
0
0
5
0.00
0.00
0.0
3.4
—
—
—
0
0
5
49
1.02
0.00
1.6
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
21.9
—
0
7
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint L12_EXFOLIATIVE and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_EXFOLIATIVE | 2.068 [1.66, 2.57] | < 0.001 |
| Birth year | 0.991 [0.98, 1.0] | 0.049 |
During the follow-up period (1.1.1998 — 31.12.2019), 324 out of 966 females with L12_EXFOLIATIVE died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_EXFOLIATIVE | 2.357 [1.97, 2.82] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.004 |
During the follow-up period (1.1.1998 — 31.12.2019), 723 out of 1728 males with L12_EXFOLIATIVE died.
Mortality risk
Mortality risk for people of age
years, who have L12_EXFOLIATIVE.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.14% | 0.419% |
| 5 | 1.185% | 2.546% |
| 10 | 2.717% | 6.481% |
| 15 | 5.238% | 11.839% |
| 20 | 9.028% | 19.972% |
Relationships between endpoints
↥Index endpoint: L12_EXFOLIATIVE – Exfoliative dermatitis
GWS hits: 2
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data